HUP0200344A2 - Gabapentinszármazék alkalmazása visceralis fájdalom megelőzésére és kezelésére - Google Patents

Gabapentinszármazék alkalmazása visceralis fájdalom megelőzésére és kezelésére

Info

Publication number
HUP0200344A2
HUP0200344A2 HU0200344A HUP0200344A HUP0200344A2 HU P0200344 A2 HUP0200344 A2 HU P0200344A2 HU 0200344 A HU0200344 A HU 0200344A HU P0200344 A HUP0200344 A HU P0200344A HU P0200344 A2 HUP0200344 A2 HU P0200344A2
Authority
HU
Hungary
Prior art keywords
visceral pain
preventing
treating visceral
gabapentin derivative
gabapentin
Prior art date
Application number
HU0200344A
Other languages
English (en)
Inventor
Justin Stephen Bryans
Laurent Diop
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of HUP0200344A2 publication Critical patent/HUP0200344A2/hu
Publication of HUP0200344A3 publication Critical patent/HUP0200344A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány visceralis fájdalom és gastrointestinalisrendellenességek, például funkcionális bélrendellenességek (functionalbowel disorders, FBD) és gyulladásos bélbetegségek (inflammatory boweldiseases, IBD) hatásos mennyiségű (I) képletű[1S-(1a,3b)]-[1-(amino-metil)-3-metil-ciklohexil]-ecetsav alkalmazásával történő megelőzéséreés kezelésére vonatkozik. Ó
HU0200344A 1999-02-23 2000-02-03 Use of gabapentin derivative for preventing and treating visceral pain HUP0200344A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99400440A EP1031350A1 (en) 1999-02-23 1999-02-23 Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain

Publications (2)

Publication Number Publication Date
HUP0200344A2 true HUP0200344A2 (hu) 2002-05-29
HUP0200344A3 HUP0200344A3 (en) 2002-11-28

Family

ID=8241887

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200344A HUP0200344A3 (en) 1999-02-23 2000-02-03 Use of gabapentin derivative for preventing and treating visceral pain

Country Status (14)

Country Link
EP (2) EP1031350A1 (hu)
JP (1) JP2002537332A (hu)
KR (1) KR20010102314A (hu)
CN (1) CN1341018A (hu)
AU (1) AU2909800A (hu)
BR (1) BR0008323A (hu)
CA (1) CA2360528A1 (hu)
CZ (1) CZ20012982A3 (hu)
EA (1) EA200100721A1 (hu)
HK (1) HK1040198A1 (hu)
HU (1) HUP0200344A3 (hu)
IL (1) IL144872A0 (hu)
NO (1) NO20014046D0 (hu)
WO (1) WO2000050027A1 (hu)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
EP1361847A2 (en) 2000-10-06 2003-11-19 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
WO2002100347A2 (en) * 2001-06-11 2002-12-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1412324A4 (en) 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
KR20030037081A (ko) * 2001-11-02 2003-05-12 한국과학기술연구원 Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법
US7045549B2 (en) 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
DE10161809A1 (de) * 2001-12-14 2003-06-26 Gruenenthal Gmbh Arzneimittel enthaltend N,N'-disubstituierte Piperazin-Verbindungen
EP1485082A4 (en) 2002-02-19 2009-12-30 Xenoport Inc PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS
WO2003080588A1 (en) 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
WO2003099338A2 (en) 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
JP4399862B2 (ja) * 2002-08-09 2010-01-20 味の素株式会社 腸疾患および内臓痛の治療薬
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
ITMI20022658A1 (it) * 2002-12-17 2004-06-18 Nicox Sa Farmaci per il dolore cronico.
MXPA06002731A (es) 2003-09-11 2006-06-05 Xenoport Inc Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba.
BRPI0414481A (pt) 2003-09-17 2006-11-14 Xenoport Inc métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
KR101096480B1 (ko) 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
EP1691811B1 (en) 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
NZ554737A (en) 2004-11-04 2011-04-29 Xenoport Inc Gabapentin prodrug sustained release oral dosage forms
EP3069731A1 (en) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2008103319A2 (en) 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
TWI380812B (zh) 2008-01-25 2013-01-01 Xenoport Inc （３ｓ）-胺甲基-５-甲基己酸前藥之晶形及使用方法
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
JP2012505238A (ja) 2008-10-08 2012-03-01 カイフィア ファーマシューティカルズ， インコーポレイテッド Ｇａｂａコンジュゲートおよびそれらの使用方法
EP2349335B1 (en) 2008-10-24 2013-08-07 ARK Diagnostics, Inc. Levetiracetam immunoassays
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
SG194974A1 (en) 2011-05-20 2013-12-30 Alderbio Holdings Llc Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
CA3048709A1 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
HUE055505T2 (hu) 2011-05-20 2021-11-29 H Lundbeck As Anti-CGRP készítmények és alkalmazásuk
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
EP2945942B1 (en) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Voriconazole immunoassays
CA2903000C (en) 2013-01-28 2021-10-12 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of .beta.-alanine and use therefor
EP2956444B1 (en) 2013-02-13 2018-05-30 ARK Diagnostics, Inc. Posaconazole immunoassays
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
FI3119431T3 (fi) 2014-03-21 2024-03-20 Teva Pharmaceuticals Int Gmbh Kalsitoniinigeeniin liittyvää peptidiä vastaan suunnattuja antagonisti-vasta-aineita ja menetelmiä niiden käyttämiseksi
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
KR20210013081A (ko) 2018-05-14 2021-02-03 엑스진 파마슈티컬 인크. 나프록센 및 프레가발린의 1-(아실옥시)-알킬 카르바메이트 약물 복합체의 결정형
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
GEP20012413B (en) * 1996-03-14 2001-04-25 Warner Lambert Co Novel Substituted Cyclic Amino Acids as Pharmaceutical Agents
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage

Also Published As

Publication number Publication date
CZ20012982A3 (cs) 2002-05-15
EP1154768A1 (en) 2001-11-21
WO2000050027A1 (en) 2000-08-31
EP1031350A1 (en) 2000-08-30
CN1341018A (zh) 2002-03-20
HUP0200344A3 (en) 2002-11-28
NO20014046L (no) 2001-08-20
AU2909800A (en) 2000-09-14
HK1040198A1 (zh) 2002-05-31
KR20010102314A (ko) 2001-11-15
NO20014046D0 (no) 2001-08-20
JP2002537332A (ja) 2002-11-05
BR0008323A (pt) 2002-01-29
CA2360528A1 (en) 2000-08-31
IL144872A0 (en) 2002-06-30
EA200100721A1 (ru) 2002-04-25

Similar Documents

Publication Publication Date Title
HUP0200344A2 (hu) Gabapentinszármazék alkalmazása visceralis fájdalom megelőzésére és kezelésére
HUP0004551A2 (hu) GABA Analógok gastrointestinalis károsodás megelőzésére és kezelésére
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
EA200600041A1 (ru) Применение изомальта (смеси 1,6-gps и 1,1-gpm) в качестве пребиотика, в частности, для получения лекарственного средства для лечения кишечных заболеваний
UA85559C2 (en) Aminobenzophenone compounds
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
WO2005072113A3 (en) Compositions and methods of treatment for inflammatory diseases
TNSN04136A1 (en) Aza-arylpiperazines
NO20073830L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
EP1689713A4 (en) BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
WO2004074243A3 (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
WO2006050861A3 (en) Statine derivatives for the treatment of alzheimer's disease
NO20044868L (no) Fremgangsmater for behandling av gastrointestinal og genitourinsmerte forstyrrelser ved bruk av vinlafaxin og derivater
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
HK1106246A1 (en) S-tenatoprazole monohydrated sodium salt and the use thereof in therapy s-
GB0407025D0 (en) Novel compounds
WO2007019888A3 (en) Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases